Illumina Joins WIN Consortium in Personalized Cancer Medicine
September 23 2015 - 5:30AM
Business Wire
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA
sequencing and array-based technologies, today announced it has
joined the Worldwide Innovative Networking (WIN) Consortium.
Founded on the recognition that greater success can be achieved
through collaboration than any organization can achieve alone, the
WIN Consortium is a global network of leading academic, industry,
insurance and non-profit research organizations working to make
personalized cancer care a reality for patients worldwide.
“We are very pleased to welcome Illumina to WIN,” said Dr. John
Mendelsohn, Chairman of the WIN Consortium and the Director of the
Khalifa Institute for Personalized Cancer Therapy at MD Anderson
Cancer Center. “Their expertise will be invaluable as we work
to accelerate the pace and reduce the cost of translating novel
cancer treatments to the bedside by developing and applying,
through worldwide clinical trials, the most promising advances in
genomic-based cancer research.”
“The WIN Consortium is uniquely bringing together renowned
institutions and cancer researchers from around the world. By
working together, we will be able to generate the type of clinical
utility data needed to define the value of next-generation genomic
testing for oncology, as well as newer methods such as liquid
biopsy,” said John Leite, Vice President of Illumina’s Oncology
business. “We look forward to collaborating, with the ultimate goal
of making personalized therapy a reality for cancer patients.”
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
About the WIN Consortium
Founded in 2010, WIN is an initiative from the Institut Gustave
Roussy (France) and University of Texas MD Anderson Cancer Center
(USA). WIN is unique structurally in that it brings together
organizations from academia, business and not-for-profits to focus
on translating the latest advances in personalized cancer medicine
into the standard of care. WIN is built on the recognition that all
stakeholders in personalized cancer therapy must collaborate and
share information, in order to effectively bring the latest
innovations in personalized cancer care to the patient. WIN is a
non-profit organization formed by 40 renowned members: Academic
cancer centres (25 centers in 17 countries), companies (Blue Cross
Blue Shield, Agilent Technologies, GE Healthcare, Oracle Health
Services, Foundation Medicine, Takeda, AstraZeneca and Pfizer), and
non-profit organizations such as EORTC, CRUK and Fondation ARC. WIN
organizes an annual symposium in Paris dedicated to personalized
medicine. For further information, please
visit www.winconsortium.org and www.winsymposium.org.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150923005359/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Jennifer Temple,
858-882-6822pr@illumina.comorWIN ConsortiumVladimir Lazar,
33 66 109 15 22Vladimir.lazar@winconsortium.org
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024